Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OBIO vs MNOV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MNOV Captures Overall Composite Edge (50.2 HOLD vs 41.1 SELL), While OBIO Leads 3–2 on Growth & Valuation Pillars
MNOV Overall Winner
6-Pillar Tally: OBIO 3 – 2 MNOV (1 Tie)
Matrix Metrics: OBIO 3 – 7 MNOV
As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (50.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin).
- Growth vs. Quality Trade-Off: MNOV earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. OBIO 41.1/100 SELL) and 0.59β · 38% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OBIO vs MNOV
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
$6.58
-6.0% 1D
Market Cap
$550.9M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.18β · 88% Vol
Unified Composite Score
41.1
SELL
Tech 15.0
Fund 36.0
Flow 64.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
MNOV
Head-to-Head Winner
Medicinova, Inc.
$1.31
+3.15% 1D
Market Cap
$65.1M
TTM Revenue
$935,717
Forward P/E
8.5x
Beta / 30D Vol
0.59β · 38% Vol
Unified Composite Score
50.2
HOLD
Tech 47.0
Fund 46.0
Flow 63.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 MNOV)
1. Valuation Multiples
MNOV
Forward P/E
N/M
8.5x
Trailing P/E
N/M
8.5x
PEG Ratio
N/M
N/M
EV / Revenue
17.9x
42.5x
2. Growth & Scale
OBIO
Revenue Growth (YoY)
-89.4%
+12.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31M
$935,717
Market Cap
$550.9M
$65.1M
3. Profitability & Quality
OBIO
Gross Margin
99.6%
42.2%
Operating Margin
-195.4%
-1232.2%
Net Profit Margin
-182.5%
0.0%
Return on Equity (ROE)
-182.3%
-24.8%
4. Balance Sheet & Cash Flow
MNOV
Cash Generation (TTM)
-$64M
-$9.1M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$9.0M Net Debt (4.72x D/E)
$25M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OBIO
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
78.2% (21st %ile)
140.1% (50th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OBIO (3) vs MNOV (7)| Institutional Metric | OBIO | MNOV | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $550.9M | $65.1M | OBIO | |
| Trailing P/E Ratio | N/M | 8.5x | MNOV | |
| Forward P/E Ratio | N/M | 8.5x | MNOV | |
| Revenue Growth (YoY) | -89.4% | +12.4% | MNOV | |
| Operating Margin (TTM) | -195.4% | -1232.2% | OBIO | |
| Net Profit Margin | -182.5% | 0.0% | MNOV | |
| Return on Equity (ROE) | -182.3% | -24.8% | MNOV | |
| 52-Week Range Position | 72% ($3–$8) | 3% ($1–$4) | OBIO | |
| Beta / 30D Volatility | 1.18β · 88% Vol | 0.59β · 38% Vol | MNOV | |
| Unified Institutional Score | 41.1 / 100 (SELL) | 50.2 / 100 (HOLD) | MNOV | |
| Trailing 12M Revenue (USD) | $31M | $935,717 | Scale | |
| Gross Profit Margin (TTM) | 99.6% | 42.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 17.9x EV/Rev | N/M PEG · 42.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$64M ($9.0M Net Debt (4.72x D/E)) | -$9.1M ($25M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OBIO +27.38 pp
3M Horizon
OBIO +35.34 pp
6M Horizon
OBIO +68.5 pp
1Y Horizon
OBIO +49.59 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | MNOV Revenue | OBIO Op. Margin | MNOV Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | N/A | $0M | N/A | -1363.8% | MNOV |
| FY2021 | N/A | $0M | N/A | -253.0% | MNOV |
| FY2022 | $0M | N/A | -924.3% | N/A | OBIO |
| FY2023 | $0M | $0M | -1866.2% | -990.0% | MNOV |
| FY2024 | $0M | N/A | -2437.5% | N/A | OBIO |
| FY2025 | $30M | $0M | -154.7% | -3242.5% | OBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OBIO
CONSOLIDATION
Current IV
78.2%
IV Percentile
21st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MNOV
UNCLASSIFIED
Current IV
140.1%
IV Percentile
50th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MNOV Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OBIO vs MNOV Key Questions & Quantitative Answers
As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (50.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Growth vs. Quality Trade-Off: MNOV earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. OBIO 41.1/100 SELL) and 0.59β · 38% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 6-period historical trajectory (FY2012 to FY2025), OBIO cumulative revenue shifted N/A while MNOV shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.
MNOV screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus MNOV (-24.8% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MNOV vs OBIO · Reverse Pair
OBIO vs OABI
· Sector Peer
MNOV vs ENTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal